Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Issue 5 (May 2022)

• Record Type: Journal Article
• Authors: Ma, Ying; Zhong, Peng-Yu; Shang, Yao-Sheng; Bai, Nan; Niu, Ying; Wang, Zhi-Lu
• Is Part Of: Journal of cardiovascular pharmacology. Volume 79:Issue 5(2022)
• Page Start: 632
• Page End: 640
• Publication Date: 2022-05
• Subjects: ticagrelor -- clopidogrel -- acute coronary syndrome -- East Asian -- meta-analysis; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000001225
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Supplemental Digital Content is Available in the Text. Abstract: The risk of bleeding is high in East Asians, whether East Asian patients with acute coronary syndrome choose ticagrelor or clopidogrel is still controversial. In this study, PubMed, EMBASE, Cochrane Library database, and other sources were systematically searched. The primary efficacy outcome was all-cause death, the primary safety outcomes were any bleeding, PLATO major bleeding, and fatal bleeding. The secondary outcomes included vascular-cause death, myocardial infarction, stent thrombosis, stroke, and dyspnea. A total of 8 randomized controlled trials with 3597 patients met inclusion criteria. Compared with clopidogrel, ticagrelor had significantly higher incidence of any bleeding [risk ratio (RR), 1.63; 1.33–1.99; P < 0.00001], PLATO major bleeding (RR 1.56; 1.15–2.12; P = 0.004), and dyspnea (RR 2.60; 1.68–4.00; P < 0.00001). However, ticagrelor was associated with a significantly reduced risk of stent thrombosis (RR 0.42; 0.19–0.92; P = 0.03). There was no significant difference in the risk of all-cause death (RR 0.87; 0.64–1.24; P = 0.44), fatal bleeding (RR 2.49; 0.79–7.86; P = 0.12), vascular-cause death (RR 0.88; 1.60–0.30; P = 0.52), myocardial infarction (RR 0.89; 0.65–1.23; P = 0.49), and stroke (RR 0.84; 0.47–1.50; P = 0.56) between the 2 groups. The present findings demonstrated that ticagrelor was associated with a higher risk of any bleeding, PLATO major bleeding, and dyspnea compared with clopidogrel in East Asian patients with acute coronary syndrome. However, it significantly reduced the risk of stent thrombosis. (Registered by PROSPERO, CRD42021255215).